Plant Name: Arnica montana
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CXCR1; NPSR1; | |
| GPR55; DRD4; | |
| RECQL; PLA2G1B; PIK3R1; GLO1; MPO; AKR1B1; HSD17B2; ALOX12; ALOX15; NOX4; HSD17B10; PYGL; POLB; | |
| NEK6; DAPK1; AKT1; MET; CAMK2B; AXL; FLT3; PKN1; CDK1; PIM1; IGF1R; NUAK1; NEK2; KDR; GSK3B; SRC; PTK2; AURKB; ALK; CSNK2A1; | |
| CA2; CA6; CA9; CA12; CA5A; CA3; CA14; CA7; CA4; CA1; | |
| KDM4E; | |
| MAOA; ALOX5; XDH; | |
| BACE1; | |
| MMP13; MMP9; MMP3; MMP2; | |
| HIF1A; TP53; NFKB1; STAT6; | |
| MDM2; | |
| ABCG2; ABCC1; | |
| HTT; NPC1; XBP1; MAPT; PAX8; RAB9A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Small molecule receptor (family A GPCR) | GPR55 | G-protein coupled receptor 55 | Q9Y2T6 | CHEMBL1075322 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transferase | MDM2 | p53-binding protein Mdm-2 | Q00987 | CHEMBL5023 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | XBP1 | X-box-binding protein 1 | P17861 | CHEMBL1741176 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | PAX8 | Paired box protein Pax-8 | Q06710 | CHEMBL2362980 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.251E-10 | 5.141E-08 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.677E-10 | 9.401E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.028E-10 | 1.313E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.983E-10 | 1.829E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.611E-09 | 4.440E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, MPO, NOX4, SRC |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.846E-08 | 3.688E-06 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.325E-08 | 7.783E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.987E-08 | 1.201E-05 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, GLO1, MDM2, MMP13, MMP2, MMP3, MMP9, TP53 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.210E-07 | 1.946E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.310E-07 | 2.053E-05 | AKR1B1, AXL, CDK1, CYP1B1, MDM2, STAT6 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.252E-07 | 3.222E-05 | AURKB, CA2, CA7, HIF1A, HTT, NEK2, NPC1, NPSR1, PLA2G1B |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.243E-07 | 3.222E-05 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 2.482E-07 | 3.486E-05 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, NEK6, PKN1, SRC |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 3.010E-07 | 4.071E-05 | GSK3B, HIF1A, HTT, MDM2, NUAK1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 5.591E-07 | 7.078E-05 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 5.754E-07 | 7.160E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, PKN1 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 6.113E-07 | 7.395E-05 | ABCG2, AKT1, ALK, CAMK2B, CSNK2A1, DAPK1, DRD4, FLT3, HTT, IGF1R, KDR, MAPT, MDM2, MET, MMP9, NFKB1, PYGL, RAB9A, STAT6, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.115E-06 | 1.271E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.193E-06 | 1.346E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 1.848E-06 | 2.002E-04 | AKT1, HIF1A, MDM2, MMP9, SRC, XBP1 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.100E-06 | 2.199E-04 | AURKB, CA2, CA7, HIF1A, HTT, KDR, NEK2, NPC1, NPSR1, PLA2G1B, SRC |
| MF | GO:0005488; binding | GO:0008134; transcription factor binding | 2.662E-06 | 2.643E-04 | FLT3, GSK3B, HIF1A, HTT, NEK6, NFKB1, PIK3R1, PIM1, PKN1, SRC, TP53, XBP1 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 3.138E-06 | 3.024E-04 | AKT1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, TP53 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 3.508E-06 | 3.306E-04 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 6.942E-06 | 6.144E-04 | CSNK2A1, HIF1A, KDR, MAPT |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 7.437E-06 | 6.504E-04 | AKT1, ALOX12, AXL, CA2, CAMK2B, CDK1, CYP1B1, GPR55, GSK3B, HIF1A, KDR, MAPT, MDM2, PAX8, PIK3R1, PIM1, PTK2, SRC, STAT6, XBP1, XDH |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 8.524E-06 | 7.308E-04 | AKT1, CYP1A1, CYP1B1, FLT3, MDM2, NFKB1, NOX4, NPC1, SRC |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 8.807E-06 | 7.491E-04 | AXL, KDR, PIK3R1, PTK2, SRC |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 9.072E-06 | 7.534E-04 | GSK3B, HTT, MAPT |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 9.334E-06 | 7.644E-04 | AKT1, ALOX15, AXL, DAPK1, FLT3, GSK3B, HIF1A, NFKB1, XBP1 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 9.426E-06 | 7.687E-04 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.206E-05 | 9.482E-04 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.206E-05 | 9.482E-04 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.488E-05 | 1.141E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.488E-05 | 1.141E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.620E-05 | 1.234E-03 | CA2, CA7, HTT, KDR, NPSR1, PLA2G1B, SRC |
| BP | GO:0065007; biological regulation | GO:0031648; protein destabilization | 2.098E-05 | 1.549E-03 | HTT, MDM2, SRC, XBP1 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.101E-05 | 1.549E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 2.162E-05 | 1.575E-03 | AKT1, CYP1B1, DAPK1, GSK3B, HTT, MAPT, MMP9, NOX4, SRC, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 2.620E-05 | 1.852E-03 | AKT1, MAPT, NOX4, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 2.686E-05 | 1.893E-03 | ALOX15, GSK3B, MAPT, MET, MMP3, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.769E-05 | 1.945E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.036E-05 | 2.108E-03 | ALOX12, ALOX15, ALOX5 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 3.295E-05 | 2.263E-03 | IGF1R, KDR, PTK2, SRC |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 3.566E-05 | 2.404E-03 | AKT1, HIF1A, NOX4, PIK3R1, PYGL, XBP1 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 3.609E-05 | 2.426E-03 | ABCG2, CA12, CA2, CA7, DRD4, GPR55, HIF1A, HTT, NPSR1, PLA2G1B, TP53 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 3.676E-05 | 2.463E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.452E-05 | 2.885E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.452E-05 | 2.885E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.452E-05 | 2.885E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.452E-05 | 2.885E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0010822; positive regulation of mitochondrion organization | 5.016E-05 | 3.140E-03 | GSK3B, HIF1A, HTT, KDR, MMP9, TP53 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 5.256E-05 | 3.270E-03 | AKT1, HIF1A, MDM2, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 6.287E-05 | 3.829E-03 | AKT1, AURKB, CSNK2A1, MDM2, NUAK1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 6.295E-05 | 3.829E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 6.547E-05 | 3.958E-03 | ABCG2, CA2, CA7, DRD4, GPR55, HIF1A, HTT, NPSR1, PLA2G1B, TP53 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 7.111E-05 | 4.242E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 8.211E-05 | 4.780E-03 | MDM2, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.881E-05 | 5.089E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.416E-05 | 5.326E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0051222; positive regulation of protein transport | 9.991E-05 | 5.578E-03 | CDK1, GSK3B, HIF1A, MDM2, PIK3R1, PLA2G1B, SRC, TP53, XBP1 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 1.073E-04 | 5.946E-03 | CYP1A1, CYP1A2, MDM2 |
| BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 1.117E-04 | 6.140E-03 | AKT1, KDR, MAPT, SRC |
| BP | GO:0008152; metabolic process | GO:2000573; positive regulation of DNA biosynthetic process | 1.117E-04 | 6.140E-03 | AURKB, NEK2, NOX4, SRC |
| BP | GO:0051179; localization | GO:0043269; regulation of ion transport | 1.181E-04 | 6.462E-03 | AKT1, CA2, CA7, CAMK2B, DAPK1, DRD4, HTT, MMP9, NPSR1, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 1.186E-04 | 6.474E-03 | MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0002376; immune system process | GO:0002684; positive regulation of immune system process | 1.261E-04 | 6.844E-03 | AKT1, AXL, CA2, HIF1A, MMP2, NFKB1, PIK3R1, PLA2G1B, PTK2, SRC, STAT6, TP53, XBP1 |
| BP | GO:0022610; biological adhesion | GO:0045785; positive regulation of cell adhesion | 1.263E-04 | 6.844E-03 | AKT1, ALOX12, ALOX15, GSK3B, KDR, PIK3R1, SRC, XBP1 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.371E-04 | 7.352E-03 | CYP19A1, CYP1A2, CYP3A4 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.401E-04 | 7.478E-03 | AKR1B1, AKT1, ALOX12, ALOX15, ALOX5, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CDK1, CSNK2A1, FLT3, GLO1, GSK3B, HIF1A, HTT, MAPT, MDM2, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PTK2, PYGL, RAB9A, SRC, STAT6, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 1.414E-04 | 7.530E-03 | AKT1, HIF1A, NFKB1, SRC |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.476E-04 | 7.746E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0071480; cellular response to gamma radiation | 1.538E-04 | 7.954E-03 | MDM2, NOX4, TP53 |
| BP | GO:0051179; localization | GO:1903829; positive regulation of cellular protein localization | 1.585E-04 | 8.157E-03 | AKT1, CDK1, GSK3B, MAPT, MDM2, PIK3R1, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 1.718E-04 | 8.711E-03 | AURKB, CDK1, PKN1 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.718E-04 | 8.711E-03 | AKT1, MAPT, TP53 |
| BP | GO:0051179; localization | GO:0046903; secretion | 1.767E-04 | 8.867E-03 | ALOX5, AXL, CA2, CA9, CXCR1, DRD4, HIF1A, MMP9, MPO, NFKB1, PLA2G1B, PYGL, XDH |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.910E-04 | 9.541E-03 | AXL, IGF1R, PIK3R1 |
| BP | GO:0009987; cellular process | GO:0000226; microtubule cytoskeleton organization | 1.961E-04 | 9.718E-03 | AURKB, CDK1, HTT, MAPT, NEK2, NEK6, PTK2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.233E-21 | 2.685E-17 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.322E-16 | 1.879E-12 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.057E-14 | 1.102E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CYP19A1; CA9; CDK1; KDR; KDR; KDR; IGF1R |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | FLT3; FLT3; AKT1; HIF1A; TP53; MET; CA9; CDK1; MMP9; NFKB1; MDM2; MDM2; PIM1; MMP2; SRC; KDR; GSK3B; PTK2; CA1; IGF1R; CSNK2A1 |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; AKT1; HIF1A; TP53; MET; CA9; MMP9; MDM2; MMP2; SRC; KDR; KDR; KDR; PTK2; IGF1R; AURKB |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; MMP3; PLA2G1B; ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; KDR; IGF1R |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; ALOX5 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; TP53; TP53; MDM2; AURKB |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1 |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; IGF1R |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; AKT1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; PTK2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; MDM2 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; HIF1A; CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| NA: NA | GIST | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP13; MPO; PLA2G1B; ALOX5 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | AXL; MET; MDM2; KDR; IGF1R; IGF1R |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; MAPT |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP13; MMP3; MMP2; ALOX5 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; CYP3A4; MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; CDK1; IGF1R |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; AKT1; MMP2; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; MDM2; SRC; AURKB |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; TP53; MMP9; KDR; IGF1R |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| NA: NA | Edema | NA | CA2 |